A Clinical Research On Treatment Of Asthma By Applying Budesonide And Formoterol Inhalation

Background:Bronchial asthma is a common serious global health problem. This chronic airway disease can be accumulated in different countries, different regions and races, different age groups, severe cases can cause death. Pathogenesis of bronchial asthma complicated, There is no cure. Worldwide burden of disease related to both its heavy, effective asthma control depends on the concerted efforts of both doctors and patients. Inhalation treatment of bronchial asthma is the world's Initiative for Asthma (GINA) in the treatment of choice, wide range of clinical health workers attached to it. The role of inhalation therapy become the preferred treatment of bronchial asthma, thank to rapidly and side effects is small, easy to use, less medication and other advantages.Pathological changes of bronchial asthma mainly airway inflammation and airway smooth muscle spasm, the inflammation plays a key role. With the establishment of mechanisms of inflammation of bronchial asthma, Asthma treatment goals shift from the prevention and treatment of acute exacerbation of chronic airway inflammation and eventual elimination of asthma symptoms. Therefore, in the late 20th century, people began to study 50 used inhaled corticosteroids (ICS). Budesonide is one of the anti-inflammatory inhaled corticosteroids. Glucocorticoid receptor affinity higher. By inhibiting the aggregation and activation of inflammatory cells, epithelial cell proliferation and damage and basement membrane thickening, reduce the vascular permeability and angiogenesis, etc. And reversal of airway reactivity and ease the speed of hair caused by delayed type hypersensitivity airway inflammation and bronchial obstruction; Inhibit the release of inflammatory mediators and factor-mediated immune response, To achieve the anti-allergic inflammation and anti-inflammatory effect. While formoterol is a new highly selective in the long-actingβ2 agonist, a major role in smooth muscle cells in theβ2 receptor to relieve bronchospasm. But also has strong anti-inflammatory activity, can inhibit increased vascular permeability and airway inflammatory cells in antigen induced airway infiltration. These two types of drugs target different mechanisms of action and role, it has a good combination of complementary roles. Alone in the clinical application of ICS in moderate persistent asthma program for the poor efficacy in patients. And budesonide and formoterol in the compound preparation, the role of inflammation in asthma of different links, can be effective in reducing asthma symptoms, improve quality of life, improve lung function, decrease airway hyperresponsiveness, airway inflammation control and reduce asthma Reduce seizure frequency and severity of attacks, reduce mortality, improve patient compliance. Rapid onset, significantly improved lung function, more effective than single skin with high doses of inhaled steroid, and significantly reduce the hormone dosage, symptoms worsen rate decreased. In clinical applications, a more promising future.Objective: To investigate the budesonide and formoterol combined treatment of bronchial asthma patients with inhaled IL-17, IL-33, INF-γand pulmonary function, and to further explore the new ways of treatment of bronchial asthma.Methods: 40 cases of eligible patients with acute exacerbation of bronchial asthma were randomly divided into two groups, control group and treatment group of 20 cases. Control group of antibiotics, hormones, and other conventional treatment Doxofylline; treatment group was given conventional therapy cloth to Snyder 160μg + formoterol 4.5μg inhalation 2 times. Regimens for 2 weeks. Measured before and after treatment in patients with IL-17, IL-33, INF-γand lung function, compared two groups of patients improved after treatment with or without significant difference between the indicators to evaluate two methods treatment of bronchial asthma.Results: 1, acute exacerbation of bronchial asthma patients in vivo IL-17 levels were significantly higher in the treatment group and control group, these factors decreased the water (P <0.05), the treatment group decreased more significantly than the control group, the difference was significant Significance (P <0.05). 2, patients with acute exacerbation of bronchial asthma in vivo IL-33 levels were significantly higher in the treatment group and control group, these factors decreased the water (P<0.05), the treatment group decreased more significantly than the control group, the difference was statistically significant (P <0.01). 3, patients with acute exacerbation of bronchial asthma in vivo INF-γlevels were significantly increased in the treatment group and the conventional group had no significant change in the factor levels (P> 0.05). 4, acute exacerbation of bronchial asthma patients showed obstructive ventilatory dysfunction, it is PEF, FEV1/FVC% were reduced. After the treatment, PEF, FEV1/FVC% were significantly increased (P <0.01). The treatment group increased more significantly than the control group (P <0.01).Conclusion 1, in patients with acute exacerbation of bronchial asthma, IL-17, IL-33 levels were higher than normal level, this result is consistent with our expected, INF-γlevels lower than normal, the budesonide and formoterol combined spray Inhalation therapy IL-17, IL-33 were higher than those before the fall (P <0.05), INF-γlevels had no significant change over the previous (P> 0.05).2, acute attack of bronchial asthma lung function was obstructive ventilatory dysfunction, and formoterol budesonide inhalation therapy combined can effectively improve lung function. 3, budesonide and formoterol inhalation therapy combined with good complementary role, the effect is superior to conventional therapy, it is recommended.